GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compugen Ltd (NAS:CGEN) » Definitions » YoY EPS Growth

CGEN (Compugen) YoY EPS Growth : 109.09% (As of Sep. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Compugen YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Compugen's YoY EPS Growth for the quarter that ended in Sep. 2024 was 109.09%.

Compugen's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was $0.01.

Compugen YoY EPS Growth Historical Data

The historical data trend for Compugen's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compugen YoY EPS Growth Chart

Compugen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.88 13.95 -10.81 4.88 46.15

Compugen Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.43 400.00 27.27 81.82 109.09

Compugen YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Compugen's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-0.21--0.39)/ | -0.39 |
=46.15 %

Compugen's YoY EPS Growth for the quarter that ended in Sep. 2024 is calculated as:

YoY EPS Growth (Q: Sep. 2024 )
=(Earnings per Share (Diluted) (Q: Sep. 2024 )-Earnings per Share (Diluted) (Q: Sep. 2023 )) / | Earnings per Share (Diluted) (Q: Sep. 2023 )) |
=(0.01--0.11)/ | -0.11 |
=109.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compugen YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Compugen's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Compugen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compugen Ltd (NAS:CGEN) » Definitions » YoY EPS Growth
Comparable Companies
XTAE:BONS XTAE:GFC-M XTAE:BLRX XTAE:DNA XTAE:MTLF XTAE:CBI XTAE:KDST XTAE:CANF XTAE:XTLB XTAE:EVGN VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
CGEN:Israel
Address
26 Harokmim Street, Building D, Azrieli Center, Holon, ISR, 5885849
Website
https://www.cgen.com
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.